Midday Report: Dynavax Slumps on FDA Rejection; U.S. Stocks Fluctuate

U.S. stocks fluctuated as Wall Street picked apart the likely policies of President-elect Donald Trump. Appearing on 60 Minutes Sunday, Trump outlined his plans to appoint an anti-abortion Justice and offered few details on his proposed wall along the southern U.S. border and plans to replace Obamacare. AK Steel (AKS) - Get Report benefited from Trump's proposed infrastructure spending, though. Morgan Stanley boosted its rating to OVERWEIGHT from EQUAL WEIGHT, pointing to proposed stimulus policies. Dynavax (DVAX) - Get Report plummeted after the FDA rejected a marketing application for a hepatitis B vaccine. The drugmaker now needs to partner with another pharmaceutical company or a financial backer to resubmit for approval. Twitter (TWTR) - Get Report climbed after hedge fund Jana Partners disclosed a new stake of nearly three million shares. Jana also disclosed a sole share stake in Yahoo! (YHOO) and dissolved its sole share stake in Expedia (EXPE) - Get Report .